4th Macrophage-directed Therapies Summit

The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston - and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.

Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.

Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:

. CD47 targeting and other 'don't eat me' signals
. Safety concerns due to model translatability and dosing
. Optimal combination or monotherapy discovery
. Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.

https://macrophage-directed-therapies.com/

4-6 October, 2022
9.00am-5:00pm EST 

Contact:
[email protected]

URLs:
Brochure: https://go.evvnt.com/1174089-0?pid=2809
Tickets: https://go.evvnt.com/1174089-2?pid=2809

Prices:
Drug Developers (Earlybird rates and Pre-Bootcamp available): USD 2099.00,
Academic (Earlybird rates and Pre-Bootcamp available): USD 1699.00,
Service Providers (Earlybird rates and Pre-Bootcamp available): USD 2699.00

Speakers: Stuart Hughes Chief Executive Officer Pathios Therapeutics, Wim Dokter Chief Scientific Officer Byondis, Stephane Peluso Chief Scientific Officer Infinity Pharmaceuticals, Rita Barcia Vice President, Process Development and Operations SIRPant Immunotherapeutics, Tatiana Novobrantseva Co-Founder and Chief Scientific Officer  Verseau Therapeutics, Jessica Haverkamp Associate Director, Macrophage Biology  BlueRock Therapeutics, Stefan Irion Senior Vice President and Head of Research BlueRock Therapeutics, Dalia Burzyn Director, Immuno- Oncology and Inflammation  Codiak BioSciences, Chen Ankri Head of Clinical and Non-Clinical Pharmacology  Enlivex Therapeutics Ltd, Juho Jalkanen Chief Operating Officer  Faron Pharmaceuticals, Lisa Johnson Senior Research Scientist, Biomarker Sciences Gilead Sciences, Mark Williams Lecturer in Cell and Molecular Biology  Glasgow Caledonian University, Stefano Sammicheli Director, Innate Cell Engagers  Ichnos Sciences, Loui Madakamutil Chief Scientific Officer ImCheck Therapeutics, Haley Laken Senior Vice President, Program and Portfolio Strategy Jounce Therapeutics, Yaron Pereg Chief Executive Officer  KAHR Bio, Krzysztof Wicher Vice President, Head of Drug Discovery  Macomics, Nicolas Poirier Chief Scientific Officer  OSE Immunotherapeutics, Leonard Reyno Executive Vice President and Chief Medical Officer  Pionyr Immunotherapeutics, Nadine Jahchan Associate Director, Research  Pionyr Immunotherapeutics, Ramona Swaby Vice President, Clinical Development Carisma Therapeutics, Kipp Weiskopf Whitehead Fellow Whitehead MIT, Amit Agarwal Senior Vice President, Clinical Development Arch Oncology, Jaume Pons President and Chief Executive Officer  ALX Oncology, Michael Klichinsky Co-Founder and Chief Scientific Officer Carisma Therapeutics, Carol O'Hear Vice President, Clinical Development, Hematology Franchise Head Gilead Sciences, Randolf Kerschbaumer Chief Executive Officer  OncoOne, Debashis Sahoo Associate Professor, Pediatrics, University of California, Founding Director  Boolean Lab, Meenal Datta Assistant Professor, Aerospace and Mechanical Engineering  University of Notre Dame, Roy Maute Co-Founder and Chief Scientific Officer  Pheast Therapeutics, Amira Barkal Co-Founder and Chief Executive Officer Pheast Therapeutics

Read More

View Less